Cohance Lifesciences (BOM:543064) Research & Development: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543064 Cohance Lifesciences Ltd BOM:543064
87 GF Score
Price ₹425.40
GF Value ₹695.81
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cohance Lifesciences Research & Development?

Cohance Lifesciences BOM:543064 -0.07% 87 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:543064 with a GF Score™ of 87/100 and a GF Value™ of ₹695.81 (Possible Value Trap). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Cohance Lifesciences's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Cohance Lifesciences  (BOM:543064) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cohance Lifesciences Research & Development Related Terms

Cohance Lifesciences Research & Development Historical Data

* Premium members only.

The historical data trend for Cohance Lifesciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cohance Lifesciences Research & Development Chart

Cohance Lifesciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 103.55 85.86 0.00 0.00 0.00

Cohance Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:543064
87GF Score
Cohance Lifesciences Ltd BOM:543064
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cohance Lifesciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Cohance Lifesciences (BOM:543064) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Cohance Lifesciences and its competitors.
Is Cohance Lifesciences' Research & Development too high?
Cohance Lifesciences' current Research & Development is ₹0 Mil. Overall, Cohance Lifesciences has a GF Score™ of 87/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cohance Lifesciences' Research & Development compare to ZTS?
Cohance Lifesciences' Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cohance Lifesciences and its competitors. Cohance Lifesciences's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cohance Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Cohance Lifesciences (BOM:543064) is currently considered Possible Value Trap. The stock's GF Value™ is ₹695.81, compared to a current price of ₹425.40 — trading 38.9% below its estimated fair value. The current Research & Development is ₹0 Mil. Cohance Lifesciences' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cohance Lifesciences (BOM:543064), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cohance Lifesciences (BOM:543064) Overvalued in 2026?

Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued. The current stock price of ₹425.40 is trading 38.9% below its estimated GF Value™ of ₹695.81. GuruFocus considers Cohance Lifesciences to be Possible Value Trap.

Key valuation signals for BOM:543064:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹695.81 vs. price of ₹425.40 (38.9% below fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the BOM:543064 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cohance Lifesciences Business Description

Other Exchanges COHANCE:India
Address Hitech City Road, Panmaktha Plot, 1, 202, 2nd Floor, B-Wing, Galaxy by Aurobindo Realty, Sy No 83/1, Hyderabad Knowledge City TSIIC Raidurg, Opposite IKEA, Hyderabad, TG, IND, 500081
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
87GF Score

Get the complete analysis for BOM:543064

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹425.40
Price
₹695.81
GF Value